STU-Na belongs to the proton pump inhibitors (PPI), a group of drugs that reduce gastric acidity. PPI are used to treat acid related diseases like erosive or ulcerative esophagitis. This trial aims to find out the therapeutic dose of STU-Na required for healing patients with erosive or ulcerative esophagitis. One of four dosages of STU-Na (15 mg, 30 mg, 60 mg, or 90 mg daily), or Esomeprazole 40 mg daily, an already marketed PPI, will be given to patients. The attribution to one of the 5 treatment groups will be by chance. Neither the patient nor the study physician will know, which treatment is administered to the patient.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
450
Unnamed facility
Calgary, Alberta, Canada
Unnamed facility
Edmonton, Alberta, Canada
Unnamed facility
Abbottsford, British Columbia, Canada
Unnamed facility
Vancouver, British Columbia, Canada
Unnamed facility
Winnipeg, Manitoba, Canada
Unnamed facility
Guelph, Ontario, Canada
Unnamed facility
Hamilton, Ontario, Canada
Unnamed facility
Scarborough Village, Ontario, Canada
Unnamed facility
Toronto, Ontario, Canada
Unnamed facility
Windsor, Ontario, Canada
...and 7 more locations
Esophageal endoscopy: assessment of achievement of grade "not present" in the Los Angeles scale of esophagitis after two weeks of treatment
Esophageal endoscopy: assessment of achievement of grade "not present" in the Los Angeles scale of esophagitis after four weeks of treatment.
Assessment of complete relief of heartburn
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.